article thumbnail

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Pharmaceutical Technology

The combination therapy also caused fewer side effects, with heart problems and hypertension as the most common ones, based on the final draft guidance. billion in 2029, while Calquence is expected to make $5.31 billion in 2029. billion in the same year. While Imbruvica sales were $3.78

article thumbnail

Managing the next pandemic: the role of nasal vaccine administration

European Pharmaceutical Review

Nasal delivery is non-invasive and provides a more targeted delivery than the systemic injectable approach, potentially offering a quicker response and reduced side effects. million by 2029, up from $122.287 million in 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029.

article thumbnail

Digitalisation of the clinical trial landscape

European Pharmaceutical Review

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 111